PARIS--(Business Wire)--
Cellectis S.A. (Paris:ALCLS), the French genome engineering specialist, has
announced that the Paris Tribunal de grande instance has dismissed the lawsuit
filed by Genoway in January 2009.
The third chamber of the Tribunal de grande instance returned today, Thursday,
November 12, a verdict stating, among other things, that the contract between
Cellectis and Genoway was terminated on December 30th, 2008, that the
under-license products detained by Genoway have to be destroyed, that the audit
of Genoway`s accounts has to be resumed and condemn Genoway to pay the sums they
owed Cellectis.
The verdict of the Tribunal de grande instance, dated November 12, 2009is
available on Cellectis` website at: http://www.cellectis.com/en/news-events/
About Cellectis S.A.
Cellectis S.A. is a world leader in genome engineering and genome surgery. The
company focuses on developing and producing custom meganucleases for use in in
vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and
research sectors. Worldwide, Cellectis has entered into more than 50 agreements
with major players in the pharma, biotech and agrobiotech industries and has
over 20 collaborations with academic research groups.
Disclaimer
This press release and the information contained herein do not constitute an
offer to sell or subscribe, or a solicitation of an offer to buy or subscribe,
shares in Cellectis in any country. This press release contains forward-looking
statements that relate to the Company`s objectives. Such forward-looking
statements are based on the current expectations and assumptions of the
Company`s management only and involve risk and uncertainties. Potential risks
and uncertainties include, without limitation, whether the Company will be
successful in implementing its strategies, whether there will be continued
growth in the relevant market and demand for the Company`s products, new
products or technological developments introduced by competitors, and risks
associated with managing growth. Unfavorable developments in connection with
these and other risks and uncertainties described, in particular, in the
Company`s prospectus prepared in connection with its IPO and on which the French
Autorité des marchés financiers ("AMF") granted its visa n° 07-023 on January
22, 2007, could cause the Company to fail to achieve the objectives expressed by
the forward-looking statements above.
Cellectis SA
Sylvie Delassus, + 33 (0)1 41 83 99 00
Senior VP Corporate Communication
media@cellectis.com
or
Alize RP
Caroline Carmagnol, +33 (0) 6 64 18 99 59
caroline@alizerp.com
Copyright Business Wire 2009
